InterVenn’s Melanoma Test Helps Oncologists Plan for Treatment
InterVenn's new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Category: Melanoma
Melanoma
Latest
Melanoma
Latest
Study Offers Promise for Multicancer Detection from a Single Blood Draw
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Melanoma
LatestMyriad’s MyPath Melanoma Test Gets Local Coverage Determination
The test will help patients receive a definitive diagnosis for suspicious skin lesion biopsies.
Asuragen Expands Oncology Portfolio
The panel accurately and sensitively detects more than 1,600 variants of clinical significance.
Read More
Bio-Rad Launches Anti-Idiotypic Antibodies Targeting Pembrolizumab and Nivolumab
Anti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read More
Liquid Biopsy Scores Immunotherapy Effectiveness
Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read More
Protagen, Gustave Roussy Partner on Risk Profiling of Cancer Patients
Protagen and Gustave Roussy will partner to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events in cancer patients treated with checkpoint inhibitors.
Read More
Delivering on the Promise of NGS for Clinical Diagnostics
Presenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
Read More
Biodesix Test May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors
Study results have demonstrated that a test based on a protein signature associated with patient outcomes in metastatic melanoma can effectively predict survival among patients receiving programmed cell death-1 antibodies.
Read More
Skin Cancer Study Shows Promise for Diagnosing a Rare Type of Melanoma
Led by investigators at the Translational Genomics Research Institute, researchers have identified a protein target that opens a window into acral lentiginous melanoma and may aid in diagnosis.
Read MoreInvestigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy
Early data suggests the test’s clinical potential for guiding anti-PD-1 therapy.
Read More
RainDance Technologies Forms Hematologic Oncology Consortium
After its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read MoreNew RUO Test Could Catch Melanoma Cancers Early
The Sentosa SA NRAS PCR test from Vela Diagnostics is the only automated NRAS qPCR test available to detect mutations related to melanoma and thyroid cancers.
Read More
bioMérieux Receives FDA Approval for THxID-BRAF Companion Diagnostic Test for Melanoma
The real-time PCR test offers clinicians a standardized, reproducible, and clinically validated method to select patients with BRAF-mutant unresectable or metastatic melanoma that may be suitable for treatment with Tafinlar and Mekinist.
Read MoreStudy: Parents Favor Genetic Tesing for Melanoma in Children
The vast majority of parents who tested positive for a genetic mutation that increases the risk of melanoma support genetic testing of their children or grandchildren.
Read More